Free Newsletter
Who said what in PhRMA's $80B deal?
Free newsletter via e-mail
Tools
PhRMA may be tired of talking about its $80 billion deal for healthcare reform, but if you're not tired of reading about it, check out Marc Ambinder's behind-the-scenes look at negotiations between the pharma lobby, Congress and the White House. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: